A novel roscovitine derivative potently induces G1-phase arrest in platelet-derived growth factor-BB-activated vascular smooth muscle cells
IM Sroka, EH Heiss, L Havlicek, F Totzke, Y Aristei… - Molecular …, 2010 - ASPET
Abnormal vascular smooth muscle cell (VSMC) proliferation contributes to the pathogenesis
of restenosis. Thus, drugs interfering with cell cycle progression in VSMC are promising …
of restenosis. Thus, drugs interfering with cell cycle progression in VSMC are promising …
[HTML][HTML] Roscovitine in cancer and other diseases
Abstract Roscovitine [CY-202,(R)-Roscovitine, Seliciclib] is a small molecule that inhibits
cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a …
cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a …
A newly synthesized Ligustrazine stilbene derivative inhibits PDGF-BB induced vascular smooth muscle cell phenotypic switch and proliferation via delaying cell cycle …
Abstract Vascular Smooth muscle cells (VSMCs) possess remarkable phenotype plasticity
that allows it to rapidly adapt to fluctuating environmental cues, including the period of …
that allows it to rapidly adapt to fluctuating environmental cues, including the period of …
[HTML][HTML] The role of pharmacokinetics and pharmacodynamics in early drug development with reference to the cyclin-dependent kinase (Cdk) inhibitor-roscovitine
M Hassan, H Sallam, Z Hassan - Sultan Qaboos University Medical …, 2011 - ncbi.nlm.nih.gov
Pharmacokinetics, pharmacodynamics and pharmacogenetics play an important role in drug
discovery and contribute to treatment success. This is an essential issue in cancer treatment …
discovery and contribute to treatment success. This is an essential issue in cancer treatment …
[HTML][HTML] Roscovitine inhibits ERK1/2 activation induced by angiotensin II in vascular smooth muscle cells
AY Li, M Han, B Zheng, JK Wen - FEBS letters, 2008 - Elsevier
Roscovitine is a potent CDK inhibitor often used as a biological tool in cell-cycle studies, but
its working mechanism and real targets in vascular smooth muscle cells (VSMCs) remain …
its working mechanism and real targets in vascular smooth muscle cells (VSMCs) remain …
Roscovitine attenuates intimal hyperplasia via inhibiting NF-κB and STAT3 activation induced by TNF-α in vascular smooth muscle cells
M He, C Wang, J Sun, Y Liu, H Wang, J Zhao… - Biochemical …, 2017 - Elsevier
Roscovitine is a selective CDK inhibitor originally designed as anti-cancer agent, which has
also been shown to inhibit proliferation in vascular smooth muscle cells (VSMCs). However …
also been shown to inhibit proliferation in vascular smooth muscle cells (VSMCs). However …
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
K Bettayeb, N Oumata, A Echalier, Y Ferandin… - Oncogene, 2008 - nature.com
Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in
clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against …
clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against …
Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study
M Kolodziej, C Goetz, P Di Fazio… - Oncology …, 2015 - spandidos-publications.com
Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …
Rubiarbonone C inhibits platelet‐derived growth factor‐induced proliferation and migration of vascular smooth muscle cells through the focal adhesion kinase, MAPK …
Background and Purpose The proliferation and migration of vascular smooth muscle cells
(VSMCs) induced by platelet‐derived growth factor (PDGF) are important steps in …
(VSMCs) induced by platelet‐derived growth factor (PDGF) are important steps in …
Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases
Small molecular inhibitors of Cyclin dependent kinases (Cdks) are currently being
developed as anticancer therapeutics due to their antiproliferative properties. The purine …
developed as anticancer therapeutics due to their antiproliferative properties. The purine …